Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2023 | Insights into the LIMBER‐103 trial

Anthony Hunter • 8 Sep 2023
SOHO 2023
Essential Thrombocythemia Myelofibrosis Myeloproliferative Neoplasms Rare Diseases INCB057643 Ruxolitinib
LIMBER‐103

Anthony Hunter, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the ongoing Phase I LIMBER‐103 study (NCT04279847), which is investigating the safety and efficacy of INCB057643, a BET inhibitor, in patients with myelofibrosis (MF) and other myeloproliferative neoplasms (MPNs) through multiple treatment arms. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Anthony Hunter

3:07
Clinical guidance for the use of JAK inhibitors when treating patients with MF
Anthony Hunter • 8 Sep 2023
2:23
Factors to consider when selecting JAK inhibitors for patients with MF
Anthony Hunter • 8 Sep 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals